The company ... GSK’s (NYSE:GSK) new vaccine for respiratory syncytial virus (RSV) and Shingrix, its shingles vaccine, fell ~69% YoY and ~4% YoY. Meanwhile, GSK’s (NYSE:GSK) full-year revenue ...

Explore how GSK's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the ...

Please consult the full Prescribing Information for additional safety information GSK is a global biopharma company with a purpose ... in GSK’s Annual Report on Form 20-F for 2023, and GSK ...

GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing ... GIST represent the most prevalent ...

reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 ...